RecruitingNCT06452732

Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML

Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in Pediatric Acute Myeloid Leukaemia: a Prospective Study


Sponsor

Peking University People's Hospital

Enrollment

283 participants

Start Date

Nov 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Leukaemia is a major disease that seriously endangers human health, the long-term survival rate of acute myeloid leukaemia receiving conventional chemotherapy is only 10% to 45%, haematological relapse is the main cause of treatment failure in acute myeloid leukaemia, reducing the relapse rate is the key to improving the efficacy of acute leukaemia, biomarker-guided preemptive therapy is an effective way to reduce the recurrence of leukaemia, existing markers to predict the recurrence has a high false Existing markers have high false-negative and false-positive rates for predicting relapse, and improving the accuracy of leukaemia relapse prediction is a major clinical problem that needs to be solved urgently. The group has found that circulating leukaemia stem cells remaining after chemotherapy are the key to relapse, therefore, we propose to conduct a multicentre prospective clinical study on the prediction of acute leukaemia relapse by circulating leukaemia stem cells.


Eligibility

Max Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses advanced blood and bone marrow testing to detect leukemia stem cells — the rare "root" cells that can cause relapse — in children newly diagnosed with acute myeloid leukemia (AML). The goal is to predict which children are at higher risk of relapse so treatment can be personalized. **You may be eligible if...** - You are 18 years old or younger and have been newly diagnosed with acute myeloid leukemia (AML) - You are able to provide written consent (or a guardian can provide it) **You may NOT be eligible if...** - You have severe heart disease (pump function below 50%) - You have significant liver disease (elevated bilirubin or liver enzymes above 1.5× normal) - You have serious kidney problems - You have a severe active infection Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMFC for the determination of leukemia stem cell

MFC for the determination of leukemia stem cell


Locations(2)

Peking University People's Hospital

Beijing, Beijing Municipality, China

People's Hospital of Peking University

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06452732


Related Trials